艾迪注射液对降低结直肠癌患者化疗所致骨髓抑制的作用  

Effects of Aidi Injection on Chemotherapy Induced Myelosuppression in Patients with Colorectal Cancer

作　　者：张浩[1] 

机构地区：[1]四川省广元市第三人民医院药剂科,四川广元628001

出　　处：《标记免疫分析与临床》2016年第10期1181-1184,共4页Labeled Immunoassays and Clinical Medicine

摘　　要：目的 研究艾迪注射液对降低结直肠癌患者化疗导致骨髓抑制的作用。方法 以我院2012年6月至2015年8月收治的结直肠癌患者86例为观察对象,根据治疗方案分为观察组和对照组各43例。两组均采用FOLFOX-4方案,观察组在此基础上给予艾迪注射液治疗。对比两组化疗前后G-CSF的用量,WBC、Hb、RBC和PLT计数,KBS生活质量评分和体重变化,以及治疗过程中毒副作用和安全性。结果 观察组G-CSF平均用量为232.28±23.28μg,总用量8775.55μg;对照组G-CSF平均用量为471.53±87.53μg,总用量为17989.75μg。观察组G-CSF平均用量及总用量均低于对照组。治疗后两组WBC计数均有明显减少,第2-6次化疗前以及治疗后,观察组的WBC计数均高于同期的对照组（P〈0.05）;两组第4次化疗前RBC、PLT均有明显减少（P〈0.05）,治疗后Hb、RBC、PLT均有明显减少（P〈0.01）。观察组治疗后评分为“提高”的患者比例60.47%,高于对照组的32.56%（P〈0.05）;观察组治疗后体重增加的患者比例55.81%,高于对照组的27.91%（P〈0.05）;观察组神经毒性在二级以上的占4.65%、消化道毒性在二级以上的为18.60%、肝功能损伤在二级以上的占16.28%、血液毒性在2级以上的占9.3%,均低于对照组（P〈0.05）。治疗期间未出现和使用艾迪注射液有关的肝肾功能损害,尿常规未出现异常。结论 艾迪注射液能有效降低结直肠癌患者化疗所致的骨髓抑制,提高患者生活质量。Objective To explore the effects of Aidi injection on chemotherapy induced myelosuppression in patients with colorectal cancer. Methods 86 patients with colorectal cancer in our hospital from June 2012 to August 2015 were divided into treatment group and control group. There were 43 patients in each group. All patients were received FOLFOX-4 chemotherapy. Patients in treatment group were injected with Aidi injection on the top of chemotherapy. The dosages of using granulocyte colony stimulating factor （G-CSF） were observed in all patients. The change of white blood cell （WBC）, hemoglobin （Hb）, red blood cell （RBC）, and platelet （PLT） counts were observed before and after chemotherapy. The KBS scoring, body weight, adverse reaction and safety were observed. Results The average and total dosage of G-CSF used in treatment group which were 232.28 ± 23.28 μg and 8775.55 μg, which were lower than that of control groups （471.53 ± 87. 53μg and 17989.75μg （P 〈 0.01 ）. After treatment the WBC count of two groups were reduced significantly （P 〈0.01 ）. The WBC counts were higher in the treatment groups than that of the control group during the whole therapeutic process except the first chemotherapy （P 〈 0.05, P 〈 0.01 ）. Ten points or better of KBS score in the treatment group was 60.47%, which was significantly higher than 32.56% of control groups （P 〈0.05）. The body weight with lkg gain in the treatment group was 55.81%, which was higher than 27.91% in control groups （P 〈 0.05 ）. Above grade 2 neurotoxicity, gastrointestinal reaction, hepatic injury and hematotoxicity were 4.65%, 18.60%, 16.28% and 9.3% in treatment group,patient quality of life.

关 键 词：艾迪注射液 化疗 结直肠癌 骨髓抑制 FOLFOX-4 

分 类 号：R735.34[医药卫生—肿瘤]